PIKAMAB to Customize Cancer Antibody Therapies

Published: Nov 12, 2009

MENLO PARK, Calif.--(BUSINESS WIRE)--PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

Back to news